Gene expression profiling as an initial approach for mechanistic studies of toxicity and tumorigenicity of herbal plants and herbal dietary supplements

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 28, Issue 1, 2010, Pages 60-87

  Guo, Lei ^a   Mei, Nan ^a   Xia, Qingsu ^a   Chen, Tao ^a   Chan, Po Chuen ^b   Fu, Peter P ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

DNA microarray; Drug metabolizing enzyme; Drug metabolizing gene; Gene expression; Herbal dietary supplements; Toxicity; Tumorigenicity

Indexed keywords

DNA MICRO-ARRAY; DRUG METABOLIZING ENZYME; DRUG METABOLIZING GENE; DRUG-METABOLIZING ENZYMES; HERBAL DIETARY SUPPLEMENT; HERBAL DIETARY SUPPLEMENTS; TUMORIGENICITY;

ANIMALS; BIOASSAY; BIOCHIPS; DNA; ENZYMES; FOOD ADDITIVES; NUTRITION; PLANTS (BOTANY); TOXICITY; VITAMINS;

GENE EXPRESSION;

CLOZAPINE; CODEINE; CYTOCHROME P450; DIMETHYLANILINE MONOOXYGENASE; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; KAVA EXTRACT; KETOCONAZOLE; MYC PROTEIN; OLANZAPINE; PLANT EXTRACT; TAMOXIFEN; TRANSCRIPTION FACTOR NRF2;

ALZHEIMER DISEASE; ANXIETY DISORDER; BLEEDING TIME; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL COMPOSITION; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA MICROARRAY; DRUG CARCINOGENICITY; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; ENZYME REGULATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENOME ANALYSIS; GENOTOXICITY; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; LIVER TOXICITY; MICROARRAY ANALYSIS; NEUROLOGIC DISEASE; NONHUMAN; ONCOGENE MYC; PAIN; PHARMACOGENOMICS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TOXICITY TESTING;

CARCINOGENS; DIETARY SUPPLEMENTS; GENE EXPRESSION PROFILING; HERBAL MEDICINE; HUMANS; MUTAGENS;

ANIMALIA; GINKGO BILOBA;

EID: 77951240826     PISSN: 10590501     EISSN: 15324095     Source Type: Journal    
DOI: 10.1080/10590500903585416     Document Type: Review

References (74)

1. Zurer P, Hanson D. Chemistry puts herbal supplements to the test. Chemical & Engineering News 2004;82:16.
2. Ho CH, Simon JC, Shahidi F, Shao Y. Dietary supplements: an overview. Washington, DC: Dietary Supplements (ACS Symposium Series 987), American Chemical Society; 2008:2-8.
3. Arneborn P, Jansson A, Bottiger Y. [Acute hepatitis in a woman after intake of slimming pills bought via Internet]. Lakartidningen 2005;102:2071-2072 (Pubitemid 41301599)
4. Bujanda L, Palacios A, Silvarino R, Sanchez A, Munoz C. [Kava-induced acute icteric hepatitis]. Gastroenterol. Hepatol 2002;25:434-435
5. CDC. Hepatic toxicity possibly associated with kava-containing products-United States, Germany, and Switzerland, 1999-2002. Morbidity andMortality Weekly Reports (MMWR) 2002:1065-1067
6. Durazo FA, Lassman C, Han SH, Saab S, Lee NP, Kawano M, Saggi B, Gordon S, Farmer DG, Yersiz H, Goldstein RL, Ghobrial M, Busuttil RW. Fulminant liver failure due to usnic acid for weight loss. Am. J. Gastroenterol 2004;99:950-952 (Pubitemid 39090229)
7. Chan PC, Xia Q, Fu PP. Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev 2007;25:211-244 (Pubitemid 47347114)
8. Fu PP, Xia Q, Guo L, Yu H, Chan PC. Toxicity of kava kava. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev 2008;26:89-112. (Pubitemid 351347047)
9. Guo L, Shi Q, Fang JL, Mei N, Ali AA, Lewis SM, Leakey JE, Frankos VH. Review of usnic acid and Usnea barbata toxicity. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev 2008;26:317-338 (Pubitemid 352790466)
10. Gurley BJ, Swain A, BaroneGW,Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab. Dispos 2007;35:240-245 (Pubitemid 46148736)
11. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S. Herb-drug interactions: a literature review. Drugs 2005;65:1239-1282 (Pubitemid 41038418)
12. Mei N, Guo L, Liu R, Fuscoe JC, Chen T. Gene expression changes induced by the tumorigenic pyrrolizidine alkaloid riddelliine in liver of Big Blue rats. BMC Bioinformatics 2007;8 Suppl 7: S4. (Pubitemid 352015099)
13. Singh YN. Potential for interaction of kava and St. John's wort with drugs. J. Ethnopharmacol 2005;100:108-113
14. CFSAN. FDA warns consumers not to use the dietary supplement LipoKinetix. 2001. Available at http://wwwcfsanfdagov/∼dms/ds-lipohtml
15. CFSAN. Letter to distributor on hazardous dietary supplement LipoKinetix. 2001. Available at http://wwwcfsanfdagov/∼dms/ds-ltr26html
16. CFSAN. Center for Food Safety and Applied Nutrition (CFSAN): Kava-containing dietary supplements may be associated with severe liver injury. U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, Maryland, March 25, 2002. Available at http://www.cfsan.fda.gov/ ∼dms/ds-warn.html
17. FDA. FDA Public Health News, FDA announced major initiatives for dietary supplements; 2004.
18. Report on carcinogen. Available at http://ntp.niehs.nih.gov/?objectid= 72016262- BDB7-CEBA-FA60E922B18C2540
19. Borgert CJ. Predicting interactions from mechanistic information: can omic data validate theories? Toxicol. Appl. Pharmacol 2007;223:114-120
20. Borgert CJ, Quill TF, McCarty LS, Mason AM. Can mode of action predict mixture toxicity for risk assessment? Toxicol. Appl. Pharmacol 2004;201:85-96. (Pubitemid 39487156)
21. Hamadeh HK, Bushel PR, Jayadev S, Martin K, DiSorbo O, Sieber S, Bennett L, Tennant R, Stoll R, Barrett JC, Blanchard K, Paules RS, Afshari CA. Gene expression analysis reveals chemical-specific profiles. Toxicol. Sci 2002;67:219-231 (Pubitemid 34746475)
22. Waring JF, Ciurlionis R, Jolly RA, Heindel M, Ulrich RG. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett 2001;120:359-368 (Pubitemid 32375103)
23. Waters MD, Fostel JM. Toxicogenomics and systems toxicology: aims and prospects. Nat. Rev. Genet 2004;5:936-948
24. NAP. Communicating toxicogenomics information to nonexperts: a workshop summary. The National Academies Press; 2005.
25. Boverhof DR, Zacharewski TR. Toxicogenomics in risk assessment: applications and needs. Toxicol. Sci 2006;89:352-360 (Pubitemid 43125993)
26. Dix DJ, Houck KA, Martin MT, Richard AM, Setzer RW, Kavlock RJ. The Tox- Cast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci 2007;95:5-12.
27. Waring JF, Jolly RA, Ciurlionis R, Lum PY, Praestgaard JT, Morfitt DC, Buratto B, Roberts C, Schadt E, Ulrich RG. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol 2001;175:28-42. (Pubitemid 32783533)
28. Afshari CA, Nuwaysir EF, Barrett JC. Application of complementary DNA microarray technology to carcinogen identification, toxicology, and drug safety evaluation. Cancer Res 1999;59:4759-4760
29. Chen T, Guo L, Zhang L, Shi L, Fang H, Sun Y, Fuscoe JC, Mei N. Gene expression profiles distinguish the carcinogenic effects of aristolochic acid in target (kidney) and non-target (liver) tissues in rats. BMC Bioinformatics 2006;7 Suppl 2: S20. (Pubitemid 46442959)
30. Chou MW, Fu PP. Formation of DHP-derived DNA adducts in vivo from dietary supplements and chinese herbal plant extracts containing carcinogenic pyrrolizidine alkaloids. Toxicol. Ind. Health 2006;22:321-7.
31. Guo L, Li Q, Xia Q, Dial S, Chan PC, Fu P. Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract. Food Chem. Toxicol 2009;47:433-442
32. Guo L, Mei N, Liao W, Chan PC, Fu P. Ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and the myc-centered network. OMICS 2010;14:75-90.
33. Guo L, Shi.Q., Dial S, Xia Q, Mei N, Li Q, Chan PC, Fu P. Gene expression profiling in male B6C3F1 mouse livers exposed to kava identifies changes in drug metabolizing genes and potential mechanisms linked to kava toxicity. Food Chem. Toxicol 2010;48:686-696.
34. Mei N, Guo L, Fu PP, Heflich RH, Chen T. Mutagenicity of comfrey (Symphytum Officinale) in rat liver. Br. J. Cancer 2005;92:873-875 (Pubitemid 40462632)
35. Mei N, Guo L, Tseng J, Dial SL, LiaoW, Manjanatha MG. Gene expression changes associated with xenobiotic metabolism pathways in mice exposed to acrylamide. Environ. Mol. Mutagen 2008;49:741-745
36. Mei N, Guo L, Zhang L, Shi L, Sun YA, Fung C, Moland CL, Dial SL, Fuscoe JC, Chen T. Analysis of gene expression changes in relation to toxicity and tumorigenesis in the livers of Big Blue transgenic rats fed comfrey (Symphytum officinale). BMC Bioinformatics 2006;7 Suppl 2: S16. (Pubitemid 46442963)
37. Driver S, Baxter K, Williamson E. Stockley's herbal medicines interactios. Pharmaceutical Press 2009:1-11.
38. Kaplowitz N. Hepatotoxicity of herbal remedies: insights into the intricacies of plant-animal warfare and cell death. Gastroenterology 1997;113:1408-1412 (Pubitemid 27418997)
39. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug. Metab. Rev 2003;35:35-98. (Pubitemid 36249785)
40. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos 2003;31:815-832 (Pubitemid 36759050)
41. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol 2008;48:662-670 (Pubitemid 351713150)
42. Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin. Pharmacokinet 2000;38:493-504. (Pubitemid 30394314)
43. Iyer KR, Sinz MW. Characterization of Phase I and Phase II hepatic drug metabolism activities in a panel of human liver preparations. Chem. Biol. Interact 1999;118:151-169
44. Roymans D, Van Looveren C, Leone A, Parker JB, McMillian M, Johnson MD, Koganti A, Gilissen R, Silber P, Mannens G, Meuldermans W. Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. Biochem. Pharmacol 2004;67:427-437 (Pubitemid 38232883)
45. Dentali SJ. Herb safety review: kava, piper methysticum forster f. (Piperaceae). Bethesda, MD: American Herbal Products Association; 1997.
46. Campo JV, McNabb J, Perel JM, Mazariegos GV, Hasegawa SL, Reyes J. Kavainduced fulminant hepatic failure. J. Am. Acad. Child Adolesc. Psychiatry 2002;41:631-632
47. Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. J. Toxicol. Clin. Toxicol 2003;41:821-829 (Pubitemid 37499010)
48. Humberston CL, Akhtar J, Krenzelok EP. Acute hepatitis induced by kava kava. J. Toxicol. Clin. Toxicol 2003;41:109-113 (Pubitemid 36520458)
49. Parkman CA. Another FDA warning: kava supplements. Case Manager 2002;13:26-28
50. Russmann S, Barguil Y, Cabalion P, Kritsanida M, Duhet D, Lauterburg BH. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur. J. Gastroenterol. Hepatol 2003;15:1033-1036 (Pubitemid 37094305)
51. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann. Intern. Med 2001;135:68-69
52. Clayton NP, Yoshizawa K, Kissling GE, Burka LT, Chan PC, Nyska A. Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. Exp. Toxicol. Pathol 2007;58:223-236 (Pubitemid 44873076)
53. Parte P, Kupfer D. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab. Dispos 2005;33:1446-1452 (Pubitemid 41323991)
54. Klick DE, Hines RN. Mechanisms regulating human FMO3 transcription. Drug Metab. Rev 2007;39:419-442
55. Ciraulo DA, Shader RI, Greenblatt DJ, Creelman W. Drug interaction in psychiatry. Baltimore: Lippincott Williams & Wilkins; 2005.
56. Clouatre DL. Kava kava: examining new reports of toxicity. Toxicol. Lett 2004;150:85-96.
57. Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev 1994;26:165-183
58. Gonzalez FJ, Yu AM. Cytochrome P450 and xenobiotic receptor humanized mice. Annu. Rev. Pharmacol. Toxicol 2006;46:41-64.
59. Bressler R. Herb-drug interactions: interactions between kava and prescription medications. Geriatrics 2005;60:24-25 (Pubitemid 41318296)
60. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005;22:525-539 (Pubitemid 41003065)
61. Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos 2002;30:1153-1157 (Pubitemid 35265819)
62. Singh YN. Kava: an overview. J. Ethnopharmacol 1992;37:13-45.
63. Lim ST, Dragull K, Tang CS, Bittenbender HC, Efird JT, Nerurkar PV. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol. Sci 2007;97:214-221 (Pubitemid 47072170)
64. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol 2007;47:89-116. (Pubitemid 46272125)
65. Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Natl. Acad. Sci. USA 2001;98:4611-4616 (Pubitemid 32295024)
66. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. USA 2001;98:3410-3415 (Pubitemid 32220859)
67. Aleksunes LM, Manautou JE. Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol. Pathol 2007;35:459-473 (Pubitemid 46911886)
68. Shen G, Hebbar V, Nair S, Xu C, Li W, Lin W, Keum YS, Han J, Gallo MA, Kong AN. Regulation of Nrf2 transactivation domain activity. The differential effects of mitogen-activated protein kinase cascades and synergistic stimulatory effect of Raf and CREB-binding protein. J. Biol. Chem 2004;279:23052-23060 (Pubitemid 38685609)
69. Wruck CJ, Gotz ME, Herdegen T, Varoga D, Brandenburg LO, Pufe T. Kavalactones protect neural cells against amyloid beta peptide-induced neurotoxicity via extracellular signal-regulated kinase 1/2-dependent nuclear factor erythroid 2-related factor 2 activation. Mol. Pharmacol 2008;73:1785-1795 (Pubitemid 351724366)
70. Joseph A, Lee T, Moland CL, Branham WS, Fuscoe JC, Leakey JE, Allaben WT, Lewis SM, Ali AA, Desai VG. Effect of (+)-usnic acid on mitochondrial functions as measured by mitochondria-specific oligonucleotide microarray in liver of B6C3F1 mice. Mitochondrion 2009;9:149-158
71. Desai VG, Lee T, Delongchamp RR, Moland CL, Branham WS, Fuscoe JC, Leakey JE. Development of mitochondria-specific mouse oligonucleotide microarray and validation of data by real-time PCR. Mitochondrion 2007;7:322-329 (Pubitemid 47300171)
72. Fu PP, Xia Q, Lin G, Chou MW. Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab. Rev 2004;36:1-55. (Pubitemid 38387834)
73. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol 2006;2:875-894 (Pubitemid 44911538)
74. Guo L, Mei N, Dial S, Fuscoe J, Chen T. Comparison of gene expression profiles altered by comfrey and riddelliine in rat liver. BMC Bioinformatics 2007;8 Suppl 7: S22. (Pubitemid 352015083)